SlideShare ist ein Scribd-Unternehmen logo
1 von 7
Downloaden Sie, um offline zu lesen
www.aasraw.com
1 AASraw Biochemical Technology Co.,Ltd
aas14@aasraw.com
6 Questions About Afatinib on
Anti-Caners(NSCLC)
6QuestionsAboutAfatinibonAnti-Caners(NSCLC)............................................................................... 1
WhatIsAfatinib?............................................................................................................................2
WhenWeNeedAfatinib?............................................................................................................. 2
HowDoesAfatinibWork?..............................................................................................................2
WasAfatinibApprovedbyFDA?Sure............................................................................................3
WhatRisk/SideeffectsDoesAfatinibBring?.................................................................................. 4
WhatOtherResearchsAboutAfatinib?.......................................................................................... 5
❶Afatinib(BIBW2992)developmentinnon-small-celllungcancer........................................ 5
❷Afatinibinlocallyadvancedandmetastaticchordoma........................................................ 6
Reference.............................................................................................................................6
www.aasraw.com
2 AASraw Biochemical Technology Co.,Ltd
aas14@aasraw.com
What Is Afatinib?
Afatinib(CAS: 439081-18-2) is a targeted therapy drug that is also known as Giotrif. It is
used to treat non-small cell lung cancer (NSCLC) that has started to spread outside the
lung or to other parts of the body. It may also be used to treat other cancers as part of a
clinical trial.
It is best to read this information with our general information about lung cancer or the
type of cancer you have. Your doctor will talk to you about this treatment and its possible
side effects before you agree (consent) to have treatment. During treatment, you will see
a cancer doctor or nurse. This is who we mean when we mention a doctor or nurse in this
information.
When We Need Afatinib?
Afatinib may be used to treat non-small cell lung cancer (NSCLC) that has:
♦ Spread to surrounding tissues (locally advanced)
♦ Spread to other parts of the body (advanced or metastatic).
Afatinib only works for cancers that have an abnormal form of a protein called epidermal
growth factor receptor (EGFR). Tests are done on the cancer cells from a biopsy or
previous surgery to check the level of EGFR. This tells your doctor whether afatinib is
likely to work for you.
How Does Afatinib Work?
Afatinib is a potent and selective, irreversible ErbB family blocker. Afatinib covalently
binds to and irreversibly blocks signaling from all homo and heterodimers formed by the
ErbB family members EGFR (ErbB1), HER2 (ErbB2), ErbB3 and ErbB4 .
In particular, afatinib covalently binds to the kinase domains of EGFR (ErbB1), HER2
(ErbB2), and HER4 (ErbB4) and irreversibly inhibits tyrosine kinase autophosphorylation,
resulting in downregulation of ErbB signaling. Certain mutations in EGFR, including
non-resistant mutations in its kinase domain, can result in increased autophosphorylation
of the receptor, leading to receptor activation, sometimes in the absence of ligand binding,
and can support cell proliferation in NSCLC. Non-resistant mutations are defined as those
www.aasraw.com
3 AASraw Biochemical Technology Co.,Ltd
aas14@aasraw.com
occurring in exons constituting the kinase domain of EGFR that lead to increased receptor
activation and where efficacy is predicted by 1) clinically meaningful tumor shrinkage with
the recommended dose of afatinib and/or 2) inhibition of cellular proliferation or EGFR
tyrosine kinase phosphorylation at concentrations of afatinib sustainable at the
recommended dosage according to validated methods. The most commonly found of
these mutations are exon 21 L858R substitutions and exon 19 deletions.
Moreover, afatinib demonstrated inhibition of autophosphorylation and/or in vitro
proliferation of cell lines expressing wild-type EGFR and in those expressing selected
EGFR exon 19 deletion mutations, exon 21 L858R mutations, or other less common
non-resistant mutations, at afatinib concentrations achieved in patients. In addition,
afatinib inhibited in vitro proliferation of cell lines overexpressing HER2.
AASraw is the professional manufacturer of
Afatinib.
Was Afatinib Approved by FDA? Sure
Approval provides a new second-line treatment option for patients with the second largest
sub-type of non-small cell lung cancer (NSCLC), representing about 20-30% of NSCLC
cases
Approval is based on results of the LUX-Lung 8 study, which showed significantly
improved overall survival and progression-free survival compared to Tarceva (erlotinib) in
patients with squamous cell carcinoma of the lung
Afatinib is already approved in more than 60 countries for the treatment of patients with
distinct types of EGFR mutation-positive NSCLC
www.aasraw.com
4 AASraw Biochemical Technology Co.,Ltd
aas14@aasraw.com
What Risk/Side
effects Does Afatinib Bring?
Important things to remember about the side effects of afatinib:
▪ Most people will not experience all of the afatinib side effects listed.
▪ Afatinib side effects are often predictable in terms of their onset, duration, and severity.
▪ Afatinib side effects are almost always reversible and will go away after therapy is
complete.
▪ Afatinib side effects may be quite manageable. There are many options to minimize or
prevent the side effects of afatinib.
The following side effects are common (occurring in greater than 30%) for patients
taking afatinib:
▪ Diarrhea
▪ Acneiform eruption (group of skin conditions resembling acne)
▪ Mouth sores
▪ Paronychia (infection of nails)
▪ Dry mouth
www.aasraw.com
5 AASraw Biochemical Technology Co.,Ltd
aas14@aasraw.com
These are less common side effects (occurring in 10-29%) for patients receiving
afatinib:
▪ Decreased appetite
▪ Itching
▪ Weight loss
▪ Nose bleeds
▪ Cystitis (bladder infection)
▪ Cheilitis (inflammation of the lips)
▪ Fever
▪ Hypokalemia (low potassium)
▪ Conjunctivitis (pink eye)
▪ Rhinorrhea (runny nose)
▪ Elevated liver enzymes
Not all side effects are listed above. Some that are rare (occurring in less than about 10
percent of patients) are not listed here. Always inform your health care provider if you
experience any unusual symptoms.
What Other Researchs About Afatinib?
❶Afatinib(BIBW2992)developmentinnon-small-celllungcancer
Afatinib (BIBW 2992), a novel aniline–quinazoline derivative, irreversibly and equipotently
targets the intrinsic kinase activity of all active ErbB receptor family members. Preclinical
results show that afatinib is effective in lung cancer models, including those with EGF
receptor (EGFR) mutations resistant to reversible first-generation EGFR inhibitors.
Afatinib is being investigated in the LUX-Lung program, which will evaluate afatinib as a
first-line treatment in patients with EGFR-activating mutations (LUX-Lung 2, 3 and 6) and
as a second- or third-line treatment in patients that have acquired resistance to gefitinib
and/or erlotinib (LUX-Lung 1, 4 and 5). LUX-Lung 1 and 2 have demonstrated, within their
respective target groups, a significant increase in the disease control rate of 58 and 86%,
respectively, and significant prolongation of progression-free survival. Further Phase III
clinical trials are currently ongoing to assess afatinib in combination with paclitaxel
(LUX-Lung 5), and compared with cisplatin/pemetrexed (LUX-Lung 3) or
cisplatin/gemcitabine (LUX-Lung 6).
www.aasraw.com
6 AASraw Biochemical Technology Co.,Ltd
aas14@aasraw.com
AASraw is the professional manufacturer of
Afatinib.
❷Afatinibinlocallyadvancedandmetastaticchordoma
This is a Phase 2 trial studying the effectiveness of a targeted cancer drug called afatinib.
Afatinib inhibits the EGFR protein, which is believed to be involved in driving the growth of
chordoma tumors. This study is designed specifically for chordoma patients 18 years or
older with recurrent or metastatic tumors. It is currently open at Leiden University Medical
Center (LUMC) and University College London Hospital (UCLH) and will open at Istituto
dei Nazionale Tumori (INT) in Milan in the coming months. The principal investigators for
this study are Dr. Hans Gelderblom at LUMC, Dr. Silvia Stacchiotti at INT, and Dr. Sandra
Strauss at UCLH.
Epidermal Growth Factor Receptor (EGFR) is a protein found on the surface of certain
cells throughout the body. Ordinarily, EGFR helps to regulate cell growth and plays a role
in wound healing. In certain cancers, including most chordomas, EGFR becomes
overactive, leading the cancer cells to multiply out of control.
Drugs that block EGFR called “EGFR inhibitors” are approved to treat several different
types of cancer. Afatinib is an EGFR inhibitor that is currently approved to treat
non-small-cell lung cancer and is being tested in other tumor types.
Several EGFR inhibitors have been shown to slow or stop the growth of chordoma cells
and chordoma tumors in mice. Of all the EGFR inhibitors tested, afatinib was the most
effective in mouse models of chordoma. In some mouse models, it slowed the growth of
the tumors, while in others it caused the tumors to shrink considerably. This trial aims to
determine whether afatinib can shrink or stop the growth of chordoma tumors in patients
with recurrent or metastatic disease.
Reference
[1] Schubert-Zsilavecz, M, Wurglics, M, Neue Arzneimittel Frühjahr 2013. (in German)
[2] Spreitzer H (13 May 2008). “Neue Wirkstoffe – Tovok”. Österreichische
Apothekerzeitung (in German) (10/2008): 498.
[3] Li D, Ambrogio L, Shimamura T, Kubo S, Takahashi M, Chirieac LR, et al. (August
2008). “BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung
www.aasraw.com
7 AASraw Biochemical Technology Co.,Ltd
aas14@aasraw.com
cancer models”. Oncogene. 27 (34): 4702–11. doi:10.1038/onc.2008.109. PMC 2748240.
PMID 18408761.
[4] “Giotrif : EPAR -Product Information” (PDF). European Medicines Agency. Boehringer
Ingelheim International GmbH. 16 October 2013. Retrieved 28 January 2014.
[5] Kobayashi Y, Togashi Y, Yatabe Y, Mizuuchi H, Jangchul P, Kondo C, et al.
(December 2015). “EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of
Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or
Third-Generation TKIs”. Clinical Cancer Research. 21 (23): 5305–13.
doi:10.1158/1078-0432.CCR-15-1046. PMID 26206867.
[6] Lin NU, Winer EP, Wheatley D, Carey LA, Houston S, Mendelson D, et al. (June 2012).
“A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients
with HER2-positive metastatic breast cancer progressing after trastuzumab”. Breast
Cancer Research and Treatment. 133 (3): 1057–65. doi:10.1007/s10549-012-2003-y.
PMC 3387495. PMID 22418700.

Weitere ähnliche Inhalte

Was ist angesagt?

1-s2.0-S2211124714001612-main
1-s2.0-S2211124714001612-main1-s2.0-S2211124714001612-main
1-s2.0-S2211124714001612-mainAnirudh Prahallad
 
LUNG CANCER TREATMENT BY NIVOLUMAB
LUNG CANCER TREATMENT BY NIVOLUMABLUNG CANCER TREATMENT BY NIVOLUMAB
LUNG CANCER TREATMENT BY NIVOLUMABHeena Parveen
 
Manejo oncológico del cáncer de pulmón
Manejo oncológico del cáncer de pulmónManejo oncológico del cáncer de pulmón
Manejo oncológico del cáncer de pulmónjalmenarez
 
Clinical studies erbitux
Clinical studies  erbituxClinical studies  erbitux
Clinical studies erbituxeman youssif
 
Clinical studies erbitux
Clinical studies  erbituxClinical studies  erbitux
Clinical studies erbituxeman youssif
 
EGFR TKIs Combinding the inhibition of RAS-ERK signaling in NSCLC Treatment
EGFR TKIs Combinding the inhibition of RAS-ERK signaling in NSCLC TreatmentEGFR TKIs Combinding the inhibition of RAS-ERK signaling in NSCLC Treatment
EGFR TKIs Combinding the inhibition of RAS-ERK signaling in NSCLC Treatmentasclepiuspdfs
 
FLT3 INHIBITORS
FLT3 INHIBITORSFLT3 INHIBITORS
FLT3 INHIBITORSspa718
 
PD1 & PD L1 Targeted Agents - Nivolumab Clinical & Commercial Development (11...
PD1 & PD L1 Targeted Agents - Nivolumab Clinical & Commercial Development (11...PD1 & PD L1 Targeted Agents - Nivolumab Clinical & Commercial Development (11...
PD1 & PD L1 Targeted Agents - Nivolumab Clinical & Commercial Development (11...Will Roettger
 
Mechanism of resistance to target therapy
Mechanism of resistance to target therapyMechanism of resistance to target therapy
Mechanism of resistance to target therapyVito Lorusso
 
LLA 2011 - S. Metzelder - Targeted therapy in leukaemia: New avenues
LLA 2011 - S. Metzelder - Targeted therapy in leukaemia: New avenuesLLA 2011 - S. Metzelder - Targeted therapy in leukaemia: New avenues
LLA 2011 - S. Metzelder - Targeted therapy in leukaemia: New avenuesEuropean School of Oncology
 
Acquired Resistance to Targeted Therapy in EGFR and ALK-Positive Lung Cancer:...
Acquired Resistance to Targeted Therapy in EGFR and ALK-Positive Lung Cancer:...Acquired Resistance to Targeted Therapy in EGFR and ALK-Positive Lung Cancer:...
Acquired Resistance to Targeted Therapy in EGFR and ALK-Positive Lung Cancer:...H. Jack West
 
Perspectives of personalized medicine in primary liver cancer by Eric Raymond
Perspectives of personalized medicine in primary liver cancer by Eric RaymondPerspectives of personalized medicine in primary liver cancer by Eric Raymond
Perspectives of personalized medicine in primary liver cancer by Eric RaymondProf. Eric Raymond Oncologie Medicale
 
Targeted therapy in lung cancer
Targeted therapy in lung cancerTargeted therapy in lung cancer
Targeted therapy in lung cancerShriram Shenoy
 
Targeted therapy in breast cancer
Targeted therapy in breast cancerTargeted therapy in breast cancer
Targeted therapy in breast cancerdr-kannan
 

Was ist angesagt? (20)

1-s2.0-S2211124714001612-main
1-s2.0-S2211124714001612-main1-s2.0-S2211124714001612-main
1-s2.0-S2211124714001612-main
 
LUNG CANCER TREATMENT BY NIVOLUMAB
LUNG CANCER TREATMENT BY NIVOLUMABLUNG CANCER TREATMENT BY NIVOLUMAB
LUNG CANCER TREATMENT BY NIVOLUMAB
 
Manejo oncológico del cáncer de pulmón
Manejo oncológico del cáncer de pulmónManejo oncológico del cáncer de pulmón
Manejo oncológico del cáncer de pulmón
 
Clinical studies erbitux
Clinical studies  erbituxClinical studies  erbitux
Clinical studies erbitux
 
Clinical studies erbitux
Clinical studies  erbituxClinical studies  erbitux
Clinical studies erbitux
 
EGFR TKIs Combinding the inhibition of RAS-ERK signaling in NSCLC Treatment
EGFR TKIs Combinding the inhibition of RAS-ERK signaling in NSCLC TreatmentEGFR TKIs Combinding the inhibition of RAS-ERK signaling in NSCLC Treatment
EGFR TKIs Combinding the inhibition of RAS-ERK signaling in NSCLC Treatment
 
erbitux
erbituxerbitux
erbitux
 
FLT3 INHIBITORS
FLT3 INHIBITORSFLT3 INHIBITORS
FLT3 INHIBITORS
 
Crizo
CrizoCrizo
Crizo
 
PD1 & PD L1 Targeted Agents - Nivolumab Clinical & Commercial Development (11...
PD1 & PD L1 Targeted Agents - Nivolumab Clinical & Commercial Development (11...PD1 & PD L1 Targeted Agents - Nivolumab Clinical & Commercial Development (11...
PD1 & PD L1 Targeted Agents - Nivolumab Clinical & Commercial Development (11...
 
Mechanism of resistance to target therapy
Mechanism of resistance to target therapyMechanism of resistance to target therapy
Mechanism of resistance to target therapy
 
LLA 2011 - S. Metzelder - Targeted therapy in leukaemia: New avenues
LLA 2011 - S. Metzelder - Targeted therapy in leukaemia: New avenuesLLA 2011 - S. Metzelder - Targeted therapy in leukaemia: New avenues
LLA 2011 - S. Metzelder - Targeted therapy in leukaemia: New avenues
 
Acquired Resistance to Targeted Therapy in EGFR and ALK-Positive Lung Cancer:...
Acquired Resistance to Targeted Therapy in EGFR and ALK-Positive Lung Cancer:...Acquired Resistance to Targeted Therapy in EGFR and ALK-Positive Lung Cancer:...
Acquired Resistance to Targeted Therapy in EGFR and ALK-Positive Lung Cancer:...
 
Perspectives of personalized medicine in primary liver cancer by Eric Raymond
Perspectives of personalized medicine in primary liver cancer by Eric RaymondPerspectives of personalized medicine in primary liver cancer by Eric Raymond
Perspectives of personalized medicine in primary liver cancer by Eric Raymond
 
egfr
egfregfr
egfr
 
Sabbatini m ilano 020318
Sabbatini m ilano 020318Sabbatini m ilano 020318
Sabbatini m ilano 020318
 
Aml flt3 itd
Aml flt3 itdAml flt3 itd
Aml flt3 itd
 
MCC 2011 - Slide 29
MCC 2011 - Slide 29MCC 2011 - Slide 29
MCC 2011 - Slide 29
 
Targeted therapy in lung cancer
Targeted therapy in lung cancerTargeted therapy in lung cancer
Targeted therapy in lung cancer
 
Targeted therapy in breast cancer
Targeted therapy in breast cancerTargeted therapy in breast cancer
Targeted therapy in breast cancer
 

Ähnlich wie 6 questions about afatinib on anti caners(nsclc)

What is erlotinib
What is erlotinibWhat is erlotinib
What is erlotinibAASraw
 
EGFR-Directed ADCs for Cancer Treatment.pdf
EGFR-Directed ADCs for Cancer Treatment.pdfEGFR-Directed ADCs for Cancer Treatment.pdf
EGFR-Directed ADCs for Cancer Treatment.pdfDoriaFang
 
Molecular targets and their significance in the management
Molecular targets and their significance in the managementMolecular targets and their significance in the management
Molecular targets and their significance in the managementdeepak2006
 
epidermal growth factor receptor (EGFR),Epidermal growth factor receptor (EGF...
epidermal growth factor receptor (EGFR),Epidermal growth factor receptor (EGF...epidermal growth factor receptor (EGFR),Epidermal growth factor receptor (EGF...
epidermal growth factor receptor (EGFR),Epidermal growth factor receptor (EGF...Bholakant raut
 
EGFR MUTANT NSCLC TTT.pptx
EGFR MUTANT NSCLC TTT.pptxEGFR MUTANT NSCLC TTT.pptx
EGFR MUTANT NSCLC TTT.pptxSeraj Aldeen
 
Fix - Off Label Chemotherapy Discussion ISMI HOTTI 2019 2019.10.31.pptx
Fix - Off Label Chemotherapy Discussion ISMI HOTTI 2019 2019.10.31.pptxFix - Off Label Chemotherapy Discussion ISMI HOTTI 2019 2019.10.31.pptx
Fix - Off Label Chemotherapy Discussion ISMI HOTTI 2019 2019.10.31.pptxfransiskusrendy
 
E1512 Trial Spotlight for May 2013 ECOG-ACRIN Newsletter
E1512 Trial Spotlight for May 2013 ECOG-ACRIN NewsletterE1512 Trial Spotlight for May 2013 ECOG-ACRIN Newsletter
E1512 Trial Spotlight for May 2013 ECOG-ACRIN NewsletterSara Bucknam
 
Hormonal treatment of breast cancer
Hormonal treatment of breast cancerHormonal treatment of breast cancer
Hormonal treatment of breast cancerSantam Chakraborty
 
study of EGFR protein expression and mutation
study of EGFR protein expression and mutation study of EGFR protein expression and mutation
study of EGFR protein expression and mutation premvarma064
 
From trials evaluating drugs to trials evaluating treatment algorithms – Focu...
From trials evaluating drugs to trials evaluating treatment algorithms – Focu...From trials evaluating drugs to trials evaluating treatment algorithms – Focu...
From trials evaluating drugs to trials evaluating treatment algorithms – Focu...Affymetrix
 
ADVANCED NONSURGICAL THERAPY FOR HEAD AND NECK CANCERS
ADVANCED NONSURGICAL THERAPY FOR  HEAD AND NECK CANCERSADVANCED NONSURGICAL THERAPY FOR  HEAD AND NECK CANCERS
ADVANCED NONSURGICAL THERAPY FOR HEAD AND NECK CANCERSNINAN THOMAS
 
Panitumumab (vectibix)
Panitumumab (vectibix)Panitumumab (vectibix)
Panitumumab (vectibix)Vibhay Pareek
 
Solid Tumors in pan-FGFR driven cancers
Solid Tumors in pan-FGFR driven cancersSolid Tumors in pan-FGFR driven cancers
Solid Tumors in pan-FGFR driven cancersAshish Jaiswal
 
Synergistic Potential of EGFR Inhibition and Thoracic Radiation for Locally A...
Synergistic Potential of EGFR Inhibition and Thoracic Radiation for Locally A...Synergistic Potential of EGFR Inhibition and Thoracic Radiation for Locally A...
Synergistic Potential of EGFR Inhibition and Thoracic Radiation for Locally A...semualkaira
 
Erlotinib 100 mg, 150mg film coated tablets smpc- taj pharmaceuticals
Erlotinib 100 mg, 150mg film coated tablets smpc- taj pharmaceuticalsErlotinib 100 mg, 150mg film coated tablets smpc- taj pharmaceuticals
Erlotinib 100 mg, 150mg film coated tablets smpc- taj pharmaceuticalsTaj Pharma
 
Breast Cancer Pharmacology Presentation - Louis Pearce.pptx
Breast Cancer Pharmacology Presentation - Louis Pearce.pptxBreast Cancer Pharmacology Presentation - Louis Pearce.pptx
Breast Cancer Pharmacology Presentation - Louis Pearce.pptxLouisPearce2
 

Ähnlich wie 6 questions about afatinib on anti caners(nsclc) (20)

What is erlotinib
What is erlotinibWhat is erlotinib
What is erlotinib
 
EGFR-Directed ADCs for Cancer Treatment.pdf
EGFR-Directed ADCs for Cancer Treatment.pdfEGFR-Directed ADCs for Cancer Treatment.pdf
EGFR-Directed ADCs for Cancer Treatment.pdf
 
Case study
Case studyCase study
Case study
 
Molecular targets and their significance in the management
Molecular targets and their significance in the managementMolecular targets and their significance in the management
Molecular targets and their significance in the management
 
epidermal growth factor receptor (EGFR),Epidermal growth factor receptor (EGF...
epidermal growth factor receptor (EGFR),Epidermal growth factor receptor (EGF...epidermal growth factor receptor (EGFR),Epidermal growth factor receptor (EGF...
epidermal growth factor receptor (EGFR),Epidermal growth factor receptor (EGF...
 
EGFR MUTANT NSCLC TTT.pptx
EGFR MUTANT NSCLC TTT.pptxEGFR MUTANT NSCLC TTT.pptx
EGFR MUTANT NSCLC TTT.pptx
 
Fix - Off Label Chemotherapy Discussion ISMI HOTTI 2019 2019.10.31.pptx
Fix - Off Label Chemotherapy Discussion ISMI HOTTI 2019 2019.10.31.pptxFix - Off Label Chemotherapy Discussion ISMI HOTTI 2019 2019.10.31.pptx
Fix - Off Label Chemotherapy Discussion ISMI HOTTI 2019 2019.10.31.pptx
 
E1512 Trial Spotlight for May 2013 ECOG-ACRIN Newsletter
E1512 Trial Spotlight for May 2013 ECOG-ACRIN NewsletterE1512 Trial Spotlight for May 2013 ECOG-ACRIN Newsletter
E1512 Trial Spotlight for May 2013 ECOG-ACRIN Newsletter
 
Hormonal treatment of breast cancer
Hormonal treatment of breast cancerHormonal treatment of breast cancer
Hormonal treatment of breast cancer
 
study of EGFR protein expression and mutation
study of EGFR protein expression and mutation study of EGFR protein expression and mutation
study of EGFR protein expression and mutation
 
From trials evaluating drugs to trials evaluating treatment algorithms – Focu...
From trials evaluating drugs to trials evaluating treatment algorithms – Focu...From trials evaluating drugs to trials evaluating treatment algorithms – Focu...
From trials evaluating drugs to trials evaluating treatment algorithms – Focu...
 
ADVANCED NONSURGICAL THERAPY FOR HEAD AND NECK CANCERS
ADVANCED NONSURGICAL THERAPY FOR  HEAD AND NECK CANCERSADVANCED NONSURGICAL THERAPY FOR  HEAD AND NECK CANCERS
ADVANCED NONSURGICAL THERAPY FOR HEAD AND NECK CANCERS
 
Egfr mutation and_tyrosine_kinase_inhibitors_(tki)_in_non small_cell_lung_can...
Egfr mutation and_tyrosine_kinase_inhibitors_(tki)_in_non small_cell_lung_can...Egfr mutation and_tyrosine_kinase_inhibitors_(tki)_in_non small_cell_lung_can...
Egfr mutation and_tyrosine_kinase_inhibitors_(tki)_in_non small_cell_lung_can...
 
Panitumumab (vectibix)
Panitumumab (vectibix)Panitumumab (vectibix)
Panitumumab (vectibix)
 
Achieving State-of-the-Art Care in Bladder Cancer in an Era of Innovative The...
Achieving State-of-the-Art Care in Bladder Cancer in an Era of Innovative The...Achieving State-of-the-Art Care in Bladder Cancer in an Era of Innovative The...
Achieving State-of-the-Art Care in Bladder Cancer in an Era of Innovative The...
 
Presentasi farmakogenomik
Presentasi farmakogenomikPresentasi farmakogenomik
Presentasi farmakogenomik
 
Solid Tumors in pan-FGFR driven cancers
Solid Tumors in pan-FGFR driven cancersSolid Tumors in pan-FGFR driven cancers
Solid Tumors in pan-FGFR driven cancers
 
Synergistic Potential of EGFR Inhibition and Thoracic Radiation for Locally A...
Synergistic Potential of EGFR Inhibition and Thoracic Radiation for Locally A...Synergistic Potential of EGFR Inhibition and Thoracic Radiation for Locally A...
Synergistic Potential of EGFR Inhibition and Thoracic Radiation for Locally A...
 
Erlotinib 100 mg, 150mg film coated tablets smpc- taj pharmaceuticals
Erlotinib 100 mg, 150mg film coated tablets smpc- taj pharmaceuticalsErlotinib 100 mg, 150mg film coated tablets smpc- taj pharmaceuticals
Erlotinib 100 mg, 150mg film coated tablets smpc- taj pharmaceuticals
 
Breast Cancer Pharmacology Presentation - Louis Pearce.pptx
Breast Cancer Pharmacology Presentation - Louis Pearce.pptxBreast Cancer Pharmacology Presentation - Louis Pearce.pptx
Breast Cancer Pharmacology Presentation - Louis Pearce.pptx
 

Mehr von AASraw

What are the top peptides for bodybuilding.pdf
What are the top peptides for bodybuilding.pdfWhat are the top peptides for bodybuilding.pdf
What are the top peptides for bodybuilding.pdfAASraw
 
What is Cannabidiphorol (CBDP)?.pdf
What is Cannabidiphorol (CBDP)?.pdfWhat is Cannabidiphorol (CBDP)?.pdf
What is Cannabidiphorol (CBDP)?.pdfAASraw
 
Is it worth taking Superdrol powder.pdf
Is it worth taking Superdrol powder.pdfIs it worth taking Superdrol powder.pdf
Is it worth taking Superdrol powder.pdfAASraw
 
Does BPC-157 help for bodybuilding.pdf
Does BPC-157 help for bodybuilding.pdfDoes BPC-157 help for bodybuilding.pdf
Does BPC-157 help for bodybuilding.pdfAASraw
 
Comprehensive Metabolic Empowerment Unveiling Tirzepatide's Multifaceted Func...
Comprehensive Metabolic Empowerment Unveiling Tirzepatide's Multifaceted Func...Comprehensive Metabolic Empowerment Unveiling Tirzepatide's Multifaceted Func...
Comprehensive Metabolic Empowerment Unveiling Tirzepatide's Multifaceted Func...AASraw
 
Healing Marvel: Harnessing TB500's Multifunctional Powers for Rapid Recovery
Healing Marvel: Harnessing TB500's Multifunctional Powers for Rapid RecoveryHealing Marvel: Harnessing TB500's Multifunctional Powers for Rapid Recovery
Healing Marvel: Harnessing TB500's Multifunctional Powers for Rapid RecoveryAASraw
 
Unlocking the Potential of CJC-1295: A Comprehensive Guide to Benefits
Unlocking the Potential of CJC-1295: A Comprehensive Guide to BenefitsUnlocking the Potential of CJC-1295: A Comprehensive Guide to Benefits
Unlocking the Potential of CJC-1295: A Comprehensive Guide to BenefitsAASraw
 
Exploring the Benefits and Risks of Melanotan II A Comprehensive Overview .pdf
Exploring the Benefits and Risks of Melanotan II A Comprehensive Overview .pdfExploring the Benefits and Risks of Melanotan II A Comprehensive Overview .pdf
Exploring the Benefits and Risks of Melanotan II A Comprehensive Overview .pdfAASraw
 
Peptide powder and finished vial on sale now.pdf
Peptide powder and finished vial on sale now.pdfPeptide powder and finished vial on sale now.pdf
Peptide powder and finished vial on sale now.pdfAASraw
 
Semaglutide: The most effective weight loss drug for type 2 diabetes
Semaglutide: The most effective weight loss drug for type 2 diabetesSemaglutide: The most effective weight loss drug for type 2 diabetes
Semaglutide: The most effective weight loss drug for type 2 diabetesAASraw
 
Special Issue:What hormones are typically used for fish sex reversal Version ...
Special Issue:What hormones are typically used for fish sex reversal Version ...Special Issue:What hormones are typically used for fish sex reversal Version ...
Special Issue:What hormones are typically used for fish sex reversal Version ...AASraw
 
Special Issue:What hormones are typically used for fish sex reversal.pdf
Special Issue:What hormones are typically used for fish sex reversal.pdfSpecial Issue:What hormones are typically used for fish sex reversal.pdf
Special Issue:What hormones are typically used for fish sex reversal.pdfAASraw
 
Which one is better, trenbolone enanthate or trenbolone acetate.pdf
Which one is better, trenbolone enanthate or trenbolone acetate.pdfWhich one is better, trenbolone enanthate or trenbolone acetate.pdf
Which one is better, trenbolone enanthate or trenbolone acetate.pdfAASraw
 
What are the benefits of testosterone cypionate, testosterone enanthate, test...
What are the benefits of testosterone cypionate, testosterone enanthate, test...What are the benefits of testosterone cypionate, testosterone enanthate, test...
What are the benefits of testosterone cypionate, testosterone enanthate, test...AASraw
 
Why Boldenone Undecylenate(Equipoise) Powder is popular.pdf
Why Boldenone Undecylenate(Equipoise) Powder is popular.pdfWhy Boldenone Undecylenate(Equipoise) Powder is popular.pdf
Why Boldenone Undecylenate(Equipoise) Powder is popular.pdfAASraw
 
What benefits can we get from pregabalin powder.pdf
What benefits can we get from pregabalin powder.pdfWhat benefits can we get from pregabalin powder.pdf
What benefits can we get from pregabalin powder.pdfAASraw
 
What dianabol powder results will you get.pdf
What dianabol powder results will you get.pdfWhat dianabol powder results will you get.pdf
What dianabol powder results will you get.pdfAASraw
 
The most discussed topic on cbd powder oils(1)
The most discussed topic on cbd powder oils(1)The most discussed topic on cbd powder oils(1)
The most discussed topic on cbd powder oils(1)AASraw
 
Azd 9291
Azd 9291Azd 9291
Azd 9291AASraw
 
Top 7 drugs for treating lung cancer approved by fda
Top 7 drugs for treating lung cancer approved by fdaTop 7 drugs for treating lung cancer approved by fda
Top 7 drugs for treating lung cancer approved by fdaAASraw
 

Mehr von AASraw (20)

What are the top peptides for bodybuilding.pdf
What are the top peptides for bodybuilding.pdfWhat are the top peptides for bodybuilding.pdf
What are the top peptides for bodybuilding.pdf
 
What is Cannabidiphorol (CBDP)?.pdf
What is Cannabidiphorol (CBDP)?.pdfWhat is Cannabidiphorol (CBDP)?.pdf
What is Cannabidiphorol (CBDP)?.pdf
 
Is it worth taking Superdrol powder.pdf
Is it worth taking Superdrol powder.pdfIs it worth taking Superdrol powder.pdf
Is it worth taking Superdrol powder.pdf
 
Does BPC-157 help for bodybuilding.pdf
Does BPC-157 help for bodybuilding.pdfDoes BPC-157 help for bodybuilding.pdf
Does BPC-157 help for bodybuilding.pdf
 
Comprehensive Metabolic Empowerment Unveiling Tirzepatide's Multifaceted Func...
Comprehensive Metabolic Empowerment Unveiling Tirzepatide's Multifaceted Func...Comprehensive Metabolic Empowerment Unveiling Tirzepatide's Multifaceted Func...
Comprehensive Metabolic Empowerment Unveiling Tirzepatide's Multifaceted Func...
 
Healing Marvel: Harnessing TB500's Multifunctional Powers for Rapid Recovery
Healing Marvel: Harnessing TB500's Multifunctional Powers for Rapid RecoveryHealing Marvel: Harnessing TB500's Multifunctional Powers for Rapid Recovery
Healing Marvel: Harnessing TB500's Multifunctional Powers for Rapid Recovery
 
Unlocking the Potential of CJC-1295: A Comprehensive Guide to Benefits
Unlocking the Potential of CJC-1295: A Comprehensive Guide to BenefitsUnlocking the Potential of CJC-1295: A Comprehensive Guide to Benefits
Unlocking the Potential of CJC-1295: A Comprehensive Guide to Benefits
 
Exploring the Benefits and Risks of Melanotan II A Comprehensive Overview .pdf
Exploring the Benefits and Risks of Melanotan II A Comprehensive Overview .pdfExploring the Benefits and Risks of Melanotan II A Comprehensive Overview .pdf
Exploring the Benefits and Risks of Melanotan II A Comprehensive Overview .pdf
 
Peptide powder and finished vial on sale now.pdf
Peptide powder and finished vial on sale now.pdfPeptide powder and finished vial on sale now.pdf
Peptide powder and finished vial on sale now.pdf
 
Semaglutide: The most effective weight loss drug for type 2 diabetes
Semaglutide: The most effective weight loss drug for type 2 diabetesSemaglutide: The most effective weight loss drug for type 2 diabetes
Semaglutide: The most effective weight loss drug for type 2 diabetes
 
Special Issue:What hormones are typically used for fish sex reversal Version ...
Special Issue:What hormones are typically used for fish sex reversal Version ...Special Issue:What hormones are typically used for fish sex reversal Version ...
Special Issue:What hormones are typically used for fish sex reversal Version ...
 
Special Issue:What hormones are typically used for fish sex reversal.pdf
Special Issue:What hormones are typically used for fish sex reversal.pdfSpecial Issue:What hormones are typically used for fish sex reversal.pdf
Special Issue:What hormones are typically used for fish sex reversal.pdf
 
Which one is better, trenbolone enanthate or trenbolone acetate.pdf
Which one is better, trenbolone enanthate or trenbolone acetate.pdfWhich one is better, trenbolone enanthate or trenbolone acetate.pdf
Which one is better, trenbolone enanthate or trenbolone acetate.pdf
 
What are the benefits of testosterone cypionate, testosterone enanthate, test...
What are the benefits of testosterone cypionate, testosterone enanthate, test...What are the benefits of testosterone cypionate, testosterone enanthate, test...
What are the benefits of testosterone cypionate, testosterone enanthate, test...
 
Why Boldenone Undecylenate(Equipoise) Powder is popular.pdf
Why Boldenone Undecylenate(Equipoise) Powder is popular.pdfWhy Boldenone Undecylenate(Equipoise) Powder is popular.pdf
Why Boldenone Undecylenate(Equipoise) Powder is popular.pdf
 
What benefits can we get from pregabalin powder.pdf
What benefits can we get from pregabalin powder.pdfWhat benefits can we get from pregabalin powder.pdf
What benefits can we get from pregabalin powder.pdf
 
What dianabol powder results will you get.pdf
What dianabol powder results will you get.pdfWhat dianabol powder results will you get.pdf
What dianabol powder results will you get.pdf
 
The most discussed topic on cbd powder oils(1)
The most discussed topic on cbd powder oils(1)The most discussed topic on cbd powder oils(1)
The most discussed topic on cbd powder oils(1)
 
Azd 9291
Azd 9291Azd 9291
Azd 9291
 
Top 7 drugs for treating lung cancer approved by fda
Top 7 drugs for treating lung cancer approved by fdaTop 7 drugs for treating lung cancer approved by fda
Top 7 drugs for treating lung cancer approved by fda
 

Kürzlich hochgeladen

DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxDNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxMAsifAhmad
 
pA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacologypA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacologyDeepakDaniel9
 
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationPhysiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationMedicoseAcademics
 
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptxBreast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptxNaveenkumar267201
 
MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.whalesdesign
 
ayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologypptayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologypptPradnya Wadekar
 
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptxANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptxWINCY THIRUMURUGAN
 
Adenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisAdenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisSujoy Dasgupta
 
Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Vaikunthan Rajaratnam
 
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdfPAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdfDolisha Warbi
 
Role of Soap based and synthetic or syndets bar
Role of  Soap based and synthetic or syndets barRole of  Soap based and synthetic or syndets bar
Role of Soap based and synthetic or syndets barmohitRahangdale
 
Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024Peter Embi
 
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdfSGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdfHongBiThi1
 
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptxORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptxNIKITA BHUTE
 
BENIGN BREAST DISEASE
BENIGN BREAST DISEASE BENIGN BREAST DISEASE
BENIGN BREAST DISEASE Mamatha Lakka
 
Using Data Visualization in Public Health Communications
Using Data Visualization in Public Health CommunicationsUsing Data Visualization in Public Health Communications
Using Data Visualization in Public Health Communicationskatiequigley33
 
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfCONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfDolisha Warbi
 
High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)kishan singh tomar
 

Kürzlich hochgeladen (20)

DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxDNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
 
pA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacologypA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacology
 
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationPhysiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
 
GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...
GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...
GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...
 
Biologic therapy ice breaking in rheumatology, Case based approach with appli...
Biologic therapy ice breaking in rheumatology, Case based approach with appli...Biologic therapy ice breaking in rheumatology, Case based approach with appli...
Biologic therapy ice breaking in rheumatology, Case based approach with appli...
 
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptxBreast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
 
MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.
 
ayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologypptayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologyppt
 
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptxANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
 
Adenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisAdenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosis
 
Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.
 
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdfPAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
 
Role of Soap based and synthetic or syndets bar
Role of  Soap based and synthetic or syndets barRole of  Soap based and synthetic or syndets bar
Role of Soap based and synthetic or syndets bar
 
Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024
 
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdfSGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdf
 
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptxORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptx
 
BENIGN BREAST DISEASE
BENIGN BREAST DISEASE BENIGN BREAST DISEASE
BENIGN BREAST DISEASE
 
Using Data Visualization in Public Health Communications
Using Data Visualization in Public Health CommunicationsUsing Data Visualization in Public Health Communications
Using Data Visualization in Public Health Communications
 
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfCONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
 
High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)
 

6 questions about afatinib on anti caners(nsclc)

  • 1. www.aasraw.com 1 AASraw Biochemical Technology Co.,Ltd aas14@aasraw.com 6 Questions About Afatinib on Anti-Caners(NSCLC) 6QuestionsAboutAfatinibonAnti-Caners(NSCLC)............................................................................... 1 WhatIsAfatinib?............................................................................................................................2 WhenWeNeedAfatinib?............................................................................................................. 2 HowDoesAfatinibWork?..............................................................................................................2 WasAfatinibApprovedbyFDA?Sure............................................................................................3 WhatRisk/SideeffectsDoesAfatinibBring?.................................................................................. 4 WhatOtherResearchsAboutAfatinib?.......................................................................................... 5 ❶Afatinib(BIBW2992)developmentinnon-small-celllungcancer........................................ 5 ❷Afatinibinlocallyadvancedandmetastaticchordoma........................................................ 6 Reference.............................................................................................................................6
  • 2. www.aasraw.com 2 AASraw Biochemical Technology Co.,Ltd aas14@aasraw.com What Is Afatinib? Afatinib(CAS: 439081-18-2) is a targeted therapy drug that is also known as Giotrif. It is used to treat non-small cell lung cancer (NSCLC) that has started to spread outside the lung or to other parts of the body. It may also be used to treat other cancers as part of a clinical trial. It is best to read this information with our general information about lung cancer or the type of cancer you have. Your doctor will talk to you about this treatment and its possible side effects before you agree (consent) to have treatment. During treatment, you will see a cancer doctor or nurse. This is who we mean when we mention a doctor or nurse in this information. When We Need Afatinib? Afatinib may be used to treat non-small cell lung cancer (NSCLC) that has: ♦ Spread to surrounding tissues (locally advanced) ♦ Spread to other parts of the body (advanced or metastatic). Afatinib only works for cancers that have an abnormal form of a protein called epidermal growth factor receptor (EGFR). Tests are done on the cancer cells from a biopsy or previous surgery to check the level of EGFR. This tells your doctor whether afatinib is likely to work for you. How Does Afatinib Work? Afatinib is a potent and selective, irreversible ErbB family blocker. Afatinib covalently binds to and irreversibly blocks signaling from all homo and heterodimers formed by the ErbB family members EGFR (ErbB1), HER2 (ErbB2), ErbB3 and ErbB4 . In particular, afatinib covalently binds to the kinase domains of EGFR (ErbB1), HER2 (ErbB2), and HER4 (ErbB4) and irreversibly inhibits tyrosine kinase autophosphorylation, resulting in downregulation of ErbB signaling. Certain mutations in EGFR, including non-resistant mutations in its kinase domain, can result in increased autophosphorylation of the receptor, leading to receptor activation, sometimes in the absence of ligand binding, and can support cell proliferation in NSCLC. Non-resistant mutations are defined as those
  • 3. www.aasraw.com 3 AASraw Biochemical Technology Co.,Ltd aas14@aasraw.com occurring in exons constituting the kinase domain of EGFR that lead to increased receptor activation and where efficacy is predicted by 1) clinically meaningful tumor shrinkage with the recommended dose of afatinib and/or 2) inhibition of cellular proliferation or EGFR tyrosine kinase phosphorylation at concentrations of afatinib sustainable at the recommended dosage according to validated methods. The most commonly found of these mutations are exon 21 L858R substitutions and exon 19 deletions. Moreover, afatinib demonstrated inhibition of autophosphorylation and/or in vitro proliferation of cell lines expressing wild-type EGFR and in those expressing selected EGFR exon 19 deletion mutations, exon 21 L858R mutations, or other less common non-resistant mutations, at afatinib concentrations achieved in patients. In addition, afatinib inhibited in vitro proliferation of cell lines overexpressing HER2. AASraw is the professional manufacturer of Afatinib. Was Afatinib Approved by FDA? Sure Approval provides a new second-line treatment option for patients with the second largest sub-type of non-small cell lung cancer (NSCLC), representing about 20-30% of NSCLC cases Approval is based on results of the LUX-Lung 8 study, which showed significantly improved overall survival and progression-free survival compared to Tarceva (erlotinib) in patients with squamous cell carcinoma of the lung Afatinib is already approved in more than 60 countries for the treatment of patients with distinct types of EGFR mutation-positive NSCLC
  • 4. www.aasraw.com 4 AASraw Biochemical Technology Co.,Ltd aas14@aasraw.com What Risk/Side effects Does Afatinib Bring? Important things to remember about the side effects of afatinib: ▪ Most people will not experience all of the afatinib side effects listed. ▪ Afatinib side effects are often predictable in terms of their onset, duration, and severity. ▪ Afatinib side effects are almost always reversible and will go away after therapy is complete. ▪ Afatinib side effects may be quite manageable. There are many options to minimize or prevent the side effects of afatinib. The following side effects are common (occurring in greater than 30%) for patients taking afatinib: ▪ Diarrhea ▪ Acneiform eruption (group of skin conditions resembling acne) ▪ Mouth sores ▪ Paronychia (infection of nails) ▪ Dry mouth
  • 5. www.aasraw.com 5 AASraw Biochemical Technology Co.,Ltd aas14@aasraw.com These are less common side effects (occurring in 10-29%) for patients receiving afatinib: ▪ Decreased appetite ▪ Itching ▪ Weight loss ▪ Nose bleeds ▪ Cystitis (bladder infection) ▪ Cheilitis (inflammation of the lips) ▪ Fever ▪ Hypokalemia (low potassium) ▪ Conjunctivitis (pink eye) ▪ Rhinorrhea (runny nose) ▪ Elevated liver enzymes Not all side effects are listed above. Some that are rare (occurring in less than about 10 percent of patients) are not listed here. Always inform your health care provider if you experience any unusual symptoms. What Other Researchs About Afatinib? ❶Afatinib(BIBW2992)developmentinnon-small-celllungcancer Afatinib (BIBW 2992), a novel aniline–quinazoline derivative, irreversibly and equipotently targets the intrinsic kinase activity of all active ErbB receptor family members. Preclinical results show that afatinib is effective in lung cancer models, including those with EGF receptor (EGFR) mutations resistant to reversible first-generation EGFR inhibitors. Afatinib is being investigated in the LUX-Lung program, which will evaluate afatinib as a first-line treatment in patients with EGFR-activating mutations (LUX-Lung 2, 3 and 6) and as a second- or third-line treatment in patients that have acquired resistance to gefitinib and/or erlotinib (LUX-Lung 1, 4 and 5). LUX-Lung 1 and 2 have demonstrated, within their respective target groups, a significant increase in the disease control rate of 58 and 86%, respectively, and significant prolongation of progression-free survival. Further Phase III clinical trials are currently ongoing to assess afatinib in combination with paclitaxel (LUX-Lung 5), and compared with cisplatin/pemetrexed (LUX-Lung 3) or cisplatin/gemcitabine (LUX-Lung 6).
  • 6. www.aasraw.com 6 AASraw Biochemical Technology Co.,Ltd aas14@aasraw.com AASraw is the professional manufacturer of Afatinib. ❷Afatinibinlocallyadvancedandmetastaticchordoma This is a Phase 2 trial studying the effectiveness of a targeted cancer drug called afatinib. Afatinib inhibits the EGFR protein, which is believed to be involved in driving the growth of chordoma tumors. This study is designed specifically for chordoma patients 18 years or older with recurrent or metastatic tumors. It is currently open at Leiden University Medical Center (LUMC) and University College London Hospital (UCLH) and will open at Istituto dei Nazionale Tumori (INT) in Milan in the coming months. The principal investigators for this study are Dr. Hans Gelderblom at LUMC, Dr. Silvia Stacchiotti at INT, and Dr. Sandra Strauss at UCLH. Epidermal Growth Factor Receptor (EGFR) is a protein found on the surface of certain cells throughout the body. Ordinarily, EGFR helps to regulate cell growth and plays a role in wound healing. In certain cancers, including most chordomas, EGFR becomes overactive, leading the cancer cells to multiply out of control. Drugs that block EGFR called “EGFR inhibitors” are approved to treat several different types of cancer. Afatinib is an EGFR inhibitor that is currently approved to treat non-small-cell lung cancer and is being tested in other tumor types. Several EGFR inhibitors have been shown to slow or stop the growth of chordoma cells and chordoma tumors in mice. Of all the EGFR inhibitors tested, afatinib was the most effective in mouse models of chordoma. In some mouse models, it slowed the growth of the tumors, while in others it caused the tumors to shrink considerably. This trial aims to determine whether afatinib can shrink or stop the growth of chordoma tumors in patients with recurrent or metastatic disease. Reference [1] Schubert-Zsilavecz, M, Wurglics, M, Neue Arzneimittel Frühjahr 2013. (in German) [2] Spreitzer H (13 May 2008). “Neue Wirkstoffe – Tovok”. Österreichische Apothekerzeitung (in German) (10/2008): 498. [3] Li D, Ambrogio L, Shimamura T, Kubo S, Takahashi M, Chirieac LR, et al. (August 2008). “BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung
  • 7. www.aasraw.com 7 AASraw Biochemical Technology Co.,Ltd aas14@aasraw.com cancer models”. Oncogene. 27 (34): 4702–11. doi:10.1038/onc.2008.109. PMC 2748240. PMID 18408761. [4] “Giotrif : EPAR -Product Information” (PDF). European Medicines Agency. Boehringer Ingelheim International GmbH. 16 October 2013. Retrieved 28 January 2014. [5] Kobayashi Y, Togashi Y, Yatabe Y, Mizuuchi H, Jangchul P, Kondo C, et al. (December 2015). “EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs”. Clinical Cancer Research. 21 (23): 5305–13. doi:10.1158/1078-0432.CCR-15-1046. PMID 26206867. [6] Lin NU, Winer EP, Wheatley D, Carey LA, Houston S, Mendelson D, et al. (June 2012). “A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab”. Breast Cancer Research and Treatment. 133 (3): 1057–65. doi:10.1007/s10549-012-2003-y. PMC 3387495. PMID 22418700.